Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions

Overview

The Research Need

Only a small fraction of new pain medications advance from safety testing in humans to approval by the U.S. Food and Drug Administration. One reason is because the research community lacks specific, measurable characteristics, or biomarker signatures, to assess pain objectively in individual patients.

About the Program

The program funds research to identify specific, reproducible characteristics of pain conditions (biomarker signatures) that reflect indicators of a normal or abnormal process, a condition or a disease, or a treatment response. These characteristics can be used to define pain levels objectively as well as to predict the development of chronic pain from injury or various diseases.

Careful selection of research participants for pain clinical studies based on these specific, measurable characteristics (called signatures or phenotypes) can improve the success of clinical trials by reducing variation among participants as well as developing a more precise set of targets. A program goal is to develop new, individualized therapies based on specific pain-related characteristics and predictive models. Novel treatments can then be tested through program-funded prospective clinical studies or through the Early Phase Pain Investigation Clinical Network (EPPIC-Net).

Because many individuals have more than one type of pain, the research leverages existing clinical studies to follow subsets of participants with two or more chronic overlapping pain conditions and determine relevant features that can serve as markers for development, progression, and treatment response to these conditions. The program also funds exploratory research, including with nonpharmacological treatments for muscles and associated soft tissues (such as fascia, a highly understudied tissue type in many painful conditions).

Upcoming Events

  • November 1, 2023 - NINDS Division of Translational Research HEAL Biomarker Webinar

Past Events

 

Program Details

To date, through the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, NIH has funded 16 awards for this program, totaling $46.3 million.

Research Examples

Research examples supported by this program include:  

  • Identifying biomarker signatures to predict which patients will develop persistent headaches after a concussion or nerve pain after a spinal cord injury
  • Using brain signals as signatures to predict pain severity and duration
  • Developing biomarker signatures to diagnose eye pain
  • Developing patient immune biomarker signatures for sickle cell disease-related pain
  • Identifying biomarker signatures in both adolescents and adults, to diagnose and monitor treatments for musculoskeletal pain
  • Discovering a novel human biomarker signature for prevention and treatment of post-operative pain
  • Manipulating myofascial tissues to test biomarker responses and potential predictive properties
  • Identifying pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics
  • Identifying and refining patient characteristics relevant to chronic overlapping pain conditions
  • Developing and validating real-world remote data from wearable devices to monitor pain experience and progression, treatment response, and quality of life

  • Beth Israel Deaconess Medical Center – Massachusetts
  • Cleveland Clinic Lerner College of Medicine, Case Western Reserve University – Ohio
  • George Mason University – Virginia
  • Johns Hopkins University – Maryland
  • Mayo Clinic Arizona – Arizona
  • Mayo Clinic Rochester – Minnesota
  • Medical College of Wisconsin – Wisconsin
  • Stanford University – California
  • Tufts Medical Center – Massachusetts
  • University of Maryland, Baltimore – Maryland
  • University of Pittsburgh – Pennsylvania
  • University of Texas Health Science Center at Houston – Texas
  • Washington University – Missouri

Funded Projects

2023
Predictive Biosignature for Endoscopic Therapy for Chronic Pancreatitis Pain
Nov 28, 2023
2023
Multi-Omic Biomarkers for Neuropathic Pain Secondary to Chemotherapy
Nov 28, 2023
2023
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
Nov 28, 2023
2023
IMPACT: Integrative Mindfulness-Based Predictive Approach for Chronic low back pain Treatment
Nov 28, 2023
2023
The Inflammatory Index as a Biomarker for Pain in Patients with Sickle Cell Disease
Nov 28, 2023

Open Funding Opportunities

2023
Biomarker Signature to Predict the Persistence of Post-Traumatic Headache
Nov 28, 2023
2023
Developing Radiocaine NaV imaging as a response monitoring biomarker for chronic pain
Nov 28, 2023
2023
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
Nov 28, 2023
2023
IMPACT: Integrative Mindfulness-Based Predictive Approach for Chronic low back pain Treatment
Nov 28, 2023
2023
Multi-Omic Biomarkers for Neuropathic Pain Secondary to Chemotherapy
Nov 28, 2023
2019
Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
Sep 25, 2019

Closed Funding Opportunities

2019
Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
Sep 25, 2019